Current impact of gene technology on healthcare. A map of economic assessments

Health Policy

Volumn 80, Issue 2, 2007, Pages 340-357

  Rogowski, Wolf ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Classification; Costs and cost analysis methods; Diffusion of innovation; Gene technology

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; BIOTECHNOLOGY; COST EFFECTIVENESS ANALYSIS; DNA EXTRACTION; ECONOMIC ASPECT; GENE TECHNOLOGY; GENETIC DISORDER; GENETIC SCREENING; GENOTYPE; HEALTH CARE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; MEDICAL RESEARCH; METHODOLOGY; PHARMACOGENETICS; PHENOTYPE; PRENATAL SCREENING; SCIENTIFIC LITERATURE;

DELIVERY OF HEALTH CARE; DIFFUSION OF INNOVATION; GENOME, HUMAN; GERMANY; HUMANS; PHARMACOGENETICS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 33845487333     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2006.03.009     Document Type: Article

References (108)

1. Human Genome Program. Genomics and its Impact on Science and Society: A 2003 Primer [online]. U.S. Department of Energy. Available online: www.ornl.gov/hgmis/publicat/primer/ [Accessed 2005, August 30].
2. Banta H.D., and Vondeling H. Strategies for successful evaluation and policy-making toward health care technology on the move: the case of medical lasers. Social Science and Medicine 12 (1994) 1663-1674
3. Guttmacher A.E., and Collins F.S. Genomic medicine - a primer. New England Journal of Medicine 19 (2002) 1512-1520
4. Cooper R.S., and Psaty B.M. Genomics and medicine: distraction, incremental progress, or the dawn of a new age?. Annals of Internal Medicine 7 (2003) 576-580
5. Jones S. Genetics in Medicine: Real Promises, Unreal Expectations [online]. New York: Milbank Memorial Fund. Available online: www.milbank.org/reports/000712genetics.html [Accessed 2005, August 26].
6. Drummond M.F. Methods for the economic evaluation of health care programmes. 3rd ed. (2005), Oxford Medical Publications, Oxford University Press, Oxford
7. Lewin B. Genes Benjamin Lewin. 8th ed. (2004), Pearson Prentice Hall, Upper Saddle River, NJ
8. Banta H.D., and Luce B.R. Health care technology and its assessment: an international perspective vol. xxii (1993), Oxford University Press, Oxford, New York p. 352
9. Zimmern R., and Cook C. Genetics and health: policy issues for genetic science and their implications for health and health services (2000), The Stationery Office, London
10. Betsch DF. Principles of Biotechnology [online]. Beltsville, MD: The National Agricultural Library. Available online: http://www.nal.usda.gov/bic/Education_res/iastate.info/bio1.html [Accessed 2006, March 17].
11. OECD. Statistical definition of biotechnology [online]. Paris, France: Organisation for Economic Co-operation and Development (OECD). Available online: http://www.oecd.org/document/42/0,2340,en_2649_37437_1933994_1_1_1_37437 ,00.html [Accessed 2006, March 7].
12. Chilcott J., et al. The role of modelling in prioritising and planning clinical trials. Health Technology Assessment 23 iii (2003) 1-125
13. Patil S.D., Rhodes D.G., and Burgess D.J. DNA-based therapeutics and DNA delivery systems: a comprehensive review. Journal of AAPS 1 (2005) E61-E77
14. Lyngstadaas A. Status and potential of gene therapy in clinical medicine. Assessment of an emerging health technology through systematic survey of clinical gene therapy protocols and published results. International Journal of Technology Assessment in Health Care 3 (2002) 645-674
15. Bender N. Gene therapy: a concept for the future in medical practice? The current state. Hamostaseologie 3 (2004) 173-178
16. CBER CfBEaR. Cellular and Gene Therapy [online], 2005. Available from URL: http://www.fda.gov/cber/gene.htm [Accessed 2005, July 28].
17. Srivastava I.K., and Liu M.A. Gene vaccines. Annals of Internal Medicine 7 (2003) 550-559
18. Wong S., and Witte O.N. The BCR-ABL story: bench to bedside and back. Annual Review of Immunology (2004) 247-306
19. Pavlou A.K., and Belsey M.J. The therapeutic antibodies market to 2008. European Journal of Pharmaceutics and Biopharmaceutics 3 (2005) 389-396
20. Pavlou A.K., and Reichert J.M. Recombinant protein therapeutics-success rates, market trends and values to 2010. Nature Biotechnology 12 (2004) 1513-1519
21. Goodman CS. Healthcare technology assessment: methods, framework, and role in policy making. American Journal of Managed Care, 1998:SP200-14; quiz SP215-6.
22. Goodman CS. Introduction to health technology assessment [online]. The Lewin Group, Falls Church, Virginia, USA: U.S. National Information Center on Health Services Research and Health Care Technology (NICHSR). Available online: http://www.nlm.nih.gov/nichsr/hta101/hta101.pdf [Accessed 2005, September 4].
23. Rogowski W. Genetic screening by DNA technology. A systematic review of health economic evidence (accepted for publication). International Journal of Technology Assessment in Health Care (2006) 3
24. Salter A.J., and Martin B.R. The economic benefits of publicly funded basic research: a critical review. Research Policy 3 (2001) 509-532
25. Martin B., Salter A., Hicks D., Pavitt K., Senker J., Sharp M., et al. The relationship between publicly funded basic research and economic performance: a SPRU review (1996), HM Treasury, London
26. Hall B.H. Industrial research during the 1980s: did the rate of return fall? In Brooking Papers. Microeconomics 2 (1993) 289-343
27. Mansfield E. Academic research and industrial innovation: an update of empirical findings. Research Policy (1998) 773-776
28. Marsili O. The anatomy and evolution of industries: technical change and industrial dynamics, in SPRU (1999), Sussex, Brighton
29. Arundel A, Van de Paal G, Soete L. PACE Report: Innovation Strategies of Europe's Largest Firms: Results of the PACE Survey for Information Sources, Public Research, Protection of Innovations, and Government Programmes. Final Report. 1995; MERIT; University of Limburg: Maastricht.
30. Kwanghui L. The relationship between research and innovation in the semiconductor and pharmaceutical industries (1981-1997). Research Policy (2004) 287-321
31. Stewart J.J., Allison P.N., and Johnson R.S. Putting a price on biotechnology. Nature Biotechnology 9 (2001) 813-817
32. DiMasi J.A., Caglarcan E., and Wood-Armany M. Emerging role of pharmacoeconomics in the research and development decision-making process. Pharmacoeconomics 7 (2001) 753-766
33. Annemans L., Genesté B., and Jolain B. Early modelling for assessing healh and economic outcomes of drug therapy. Value in Health 6 (2000) 427-434
34. Miller P. Role of pharmacoeconomic analysis in R&D decision making: when, where, how?. Pharmacoeconomics 1 (2005) 1-12
35. Mason J., and Drummond M. Biotechnology: a special case for health technology assessment?. Health Policy 1 (1997) 73-81
36. Mason J. Challenges to the economic evaluation of new biotechnological interventions in healthcare. Pharmacoeconomics 2 (1999) 119-125
37. van Rijkom J., et al. Assessment of biotechnology drugs: what are the issues?. Health Policy 3 (1999) 255-274
38. Barton P., et al. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technology Assessment 11 iii (2004) 1-91
39. Aapro M., and San Miguel J. Evolving treatment strategies for anaemia in cancer: experience with epoetin beta. Oncology (2004) 17-22
40. Marchetti M., and Barosi G. Clinical and economic impact of epoetins in cancer care. Pharmacoeconomics 16 (2004) 1029-1045
41. Goldie S.J., and Levin A.R. msJAMA. Genomics in medicine and public health: role of cost-effectiveness analysis. Journal of the American Medical Association 13 (2001) 1637-1638
42. Gazelle G.S., et al. Cost-effectiveness analysis in the assessment of diagnostic imaging technologies. Radiology 2 (2005) 361-370
43. Giacomini M., Miller F., and Browman G. Confronting the "gray zones" of technology assessment: evaluating genetic testing services for public insurance coverage in Canada. International Journal of Technology Assessment in Health Care 2 (2003) 301-316
44. Hirschhorn J.N., et al. A comprehensive review of genetic association studies. Genetics in Medicine 2 (2002) 45-61
45. Hennen L, Petermann T, Sauter A. *Das* genetische Orakel Prognosen und Diagnosen durch Gentests - eine aktuelle Bilanz Leonhard Hennen Thomas Petermann Arnold Sauter. Deutschland Büro für Technikfolgen-Abschätzung: Studien des Büros für Technikfolgen-Abschätzung beim Deutschen Bundestag 10. Berlin: Ed. Sigma, 2001: 164 S. 21 cm.
46. Giacomini M., Miller F., and O'Brien B.J. Economic considerations for health insurance coverage of emerging genetic tests. Community Genetics 2 (2003) 61-73
47. Schöffski O. Genetic testing and the health care system. European Journal of Health Economics 3 (2002) 73-76
48. Phillips K.A., et al. Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs. American Journal of Managed Care 7 Pt 1 (2004) 425-432
49. Clague A., and Thomas A. Neonatal biochemical screening for disease. Clinica Chimica Acta 1/2 (2002) 99-110
50. Damm R. Gesetzgebungsprojekt Gentestgesetz - Regelungsprinzipien und Regelungsmaterialien. Medizinrecht 1 (2004) 1-19
51. Clayton E.W. Ethical, legal, and social implications of genomic medicine. New England Journal of Medicine 6 (2003) 562-569
52. Green J.M., et al. Psychosocial aspects of genetic screening of pregnant women and newborns: a systematic review. Health Technology Assessment 33 iii, ix, x (2004) 1-109
53. Harris M., Winship I., and Spriggs M. Controversies and ethical issues in cancer-genetics clinics. Lancet Oncology 5 (2005) 301-310
54. Parker M., and Lucassen A. Working towards ethical management of genetic testing. Lancet 9346 (2002) 1685-1688
55. Veenstra D.L., Higashi M.K., and Phillips K.A. Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci 3 (2000) E29
56. Flowers C.R., and Veenstra D. The role of cost-effectiveness analysis in the era of pharmacogenomics. Pharmacoeconomics 8 (2004) 481-493
57. Phillips K.A., and Bebber S.L.V. A systematic review of cost-effectiveness analysis of pharmacogenomic interventions. Pharmacogenomics 8 (2004) 1139-1149
58. Phillips K.A., and Van Bebber S.L. Measuring the value of pharmacogenomics. Natural Review Drug Discovery 6 (2005) 500-509
59. National Screening Committee UK. First report of the National Screening Committee [online]. Leeds: Health Departments in the United Kingdom. Available online: http://www.nsc.nhs.uk/pdfs/nsc_firstreport.pdf [Accessed 2005, June 7].
60. National Screening Committee. Second Report of the UK National Screening Committee [online]. London: Department of health. Available online: http://www.nsc.nhs.uk/pdfs/secondreport.pdf [Accessed 2005, June 7].
61. Higashi M.K., et al. The cost-effectiveness of interleukin-1 genetic testing for periodontal disease. Journal of Periodontology 12 (2002) 1474-1484
62. Kinzler W.L., Morrell K., and Vintzileos A.M. Variables that underlie cost efficacy of prenatal screening. Obstetrics and Gynecology Clinics of North America 2 277-286 (2002) v-vi
63. Miller F, et al. Predictive Genetic Tests and Health Care Costs: Final Report Prepared for the Ontario Ministry of Health and Long Term Care [online]. Toronto: Ontario Ministry of Health. Available online: http://www.health.gov.on.ca/english/public/pub/ministry_reports/genetics rep02/chepa_rep.pdf [Accessed 2005, August 28].
64. Wille M.C., et al. Advances in preconception genetic counseling. Journal of Perinatal and Neonatal Nursing 1 (2004) 28-40
65. Brundage S.C., and Strossner M. Genetics issues in preconception health care. Journal of Science and Medical Association 6 (2002) 255-259
66. Krawczak M., Cooper D.N., and Schmidtke J. Estimating the efficacy and efficiency of cascade genetic screening. American Journal of Human Genetics 2 (2001) 361-370
67. Tengs T.O., and Berry D.A. The cost effectiveness of testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes. Disease Management and Clinical Outcomes (2000) 15-24
68. Dezateux C. Evaluating newborn-screening programmes based on dried blood spots: future challenges. British Medical Bulletin 4 (1998) 877-890
69. Edwards S.J., et al. Why "underpowered" trials are not necessarily unethical. Lancet 9080 (1997) 804-807
70. Butler J.R. Economic evaluations of screening programs: a review of methods and results. Clinica Chimica Acta 1/2 (2002) 31-40
71. Meyer-Lüerßen D. IVD-Weltmarkt - Schätzung für 2006 [online]. VDGH. Available online: http://www.vdgh.de/internet/Marktdaten/Diagnostikamarkt/Weltweit/weltwei t.htm [Accessed 2005, August 8].
72. Williams A. The in vitro diagnostics industry and its regulatory environment [online]. European Diagnostics Manufacturers Association. Available online: http://www.edma-ivd.be/Articles/DAW_Rapporteur_Article_Dec03.pdf [Accessed 2005, August 12].
73. Adams J. Fundamental stocks of knowledge and productivity growth. Journal of Political Economy (1990) 673-702
74. Tan-Torres E.T. World Health Organization. Making choices in health: WHO guide to cost-effectiveness analysis (2003), World Health Organization, Geneva
75. Weatherall D, et al. Genomics and World Health [online]. Newton, MA, USA: World Health Organization. Advisory Committee on Health Research. Available online: http://www3.who.int/whosis/genomics/genomics_report.cfm [Accessed 2006, March 7].
76. Broder S, Hoffman SL, Hotez PJ. Cures for the Third World's problems: the application of genomics to the diseases plaguing the developing world may have huge medical and economic benefits for those countries and might even prevent armed conflict. EMBO Report 2002; 9:806-12.
77. Morel C.M., Lauer J.A., and Evans D.B. Cost effectiveness analysis of strategies to combat malaria in developing countries. British Medical Journal 7528 (2005) 1299
78. Hogan D.R., et al. Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries. British Medical Journal 7530 (2005) 1431-1437
79. Food and Drug Administration. Guidance for industry: pharmacogenomic data submissions [online]. U.S. Department of Health and Human Services. Available online: http://www.fda.gov/cber/gdlns/pharmdtasub.pdf [Accessed 2005, September 21].
80. Lesko L.J., and Woodcock J. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Natural Review Drug Discovery 9 (2004) 763-769
81. Lesko L.J., et al. Pharmacogenetics and pharmacogenomics in drug development and regulatory decision-making: report of the first FDA-PWG-PhRMA-DruSafe Workshop. Journal of Clinical Pharmacology 4 (2003) 342-358
82. Salerno R.A., and Lesko L.J. Pharmacogenomics in drug development and regulatory decision-making: the genomic data submission (GDS) proposal. Pharmacogenomics 1 (2004) 25-30
83. Hamosh A., et al. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Research 1 (2002) 52-55
84. Gordois A., et al. Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia. British Journal of Cancer 4 (2003) 634-640
85. Leese B., Hutton J., and Maynard A. A comparison of the costs and benefits of recombinant human erythropoietin (epoetin) in the treatment of chronic renal failure in five European countries. Pharmacoeconomics 5 (1992) 346-356
86. El-Serag H.B., Inadomi J.M., and Kowdley K.V. Screening for hereditary hemochromatosis in siblings and children of affected patients. A cost-effectiveness analysis. Annals of Internal Medicine 4 (2000) 261-269
87. Marra C.A., Esdaile J.M., and Anis A.H. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine S-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. Journal of Rheumatology 12 (2002) 2507-2512
88. Weir R, et al. Polymerase chain reaction in the diagnosis and monitoring of patients with PML-RARα and PLZF-RARα gene rearrangement in acute promyelocytic leukaemia [online]. Canberra: Medical Services Advisory Committee. Available online: http://www.msac.gov.au/pdfs/reports/ref09aii.pdf [Accessed 2005, July 27].
89. Hahl J., et al. Costs of predicting IDDM. Diabetologia 1 (1998) 79-85
90. Balmana J., et al. Genetic counseling program in familial breast cancer: Analysis of its effectiveness, cost and cost-effectiveness ratio. International Journal of Cancer 4 (2004) 647
91. Noorani H.Z., et al. Cost comparison of molecular versus conventional screening of relatives at risk for retinoblastoma. American Journal of Human Genetics 2 (1996) 301-307
92. Marks D., et al. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. British Medical Journal 7349 (2002) 1303
93. Lee D.S., et al. Analysis of the costs of diagnosing cystic fibrosis with a newborn screening program. Journal of Pediatrics 6 (2003) 617-623
94. Kievit W., et al. Cost effectiveness of a new strategy to identify HNPCC patients. Gut 1 (2005) 97-102
95. Chikhaoui Y., et al. Cost-minimization analysis of genetic testing versus clinical screening of at-risk relatives for familial adenomatous polyposis. International Journal of Technology Assessment in Health Care 1 (2002) 67-80
96. Cuckle H.S., et al. Cost effectiveness of antenatal screening for cystic fibrosis. British Medical Journal 7018 (1995) 1460-1463 [1463-1464; discussion]
97. Davies S.C., et al. Screening for sickle cell disease and thalassaemia: a systematic review with supplementary research. Health Technology Assessment 3 i-v (2000) 1-99
98. Song F.J., et al. Screening for fragile X syndrome: a literature review and modelling study. Health Technology Assessment 16 (2003) 1-106
99. van der Riet A.A., van Hout B.A., and Rutten F.F. Cost effectiveness of DNA diagnosis for four monogenic diseases. Journal of Medical Genetics 9 (1997) 741-745
100. Marchetti M., Pistorio A., and Barosi G. Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden-cost-effectiveness analysis. Thrombosis and Haemostasis 5 (2000) 752-757
101. Marchetti M., Quaglini S., and Barosi G. Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A. Qjm 7 (2001) 365-372
102. Jackson B.R., et al. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 6 (2003) 721-729
103. Honey E., et al. Cost effectiveness of screening for Chlamydia trachomatis: a review of published studies. Sexually Transmitted Infections 6 (2002) 406-412
104. Elkin E.B., et al. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. Journal of Clinical Oncology 5 (2004) 854-863
105. Pandor A., et al. Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review. Health Technology Assessment 12 iii (2004) 1-121
106. Rulyak S.J., et al. Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointestinal Endoscopy 1 (2003) 23-29
107. Lieu T.A., Watson S.E., and Washington A.E. The cost-effectiveness of prenatal carrier screening for cystic fibrosis. Obstetrics and Gynecology 6 (1994) 903-912
108. Schöffski O., Schmidtke J., and Stuhrmann M. Cost-effectiveness of population-based genetic hemochromatosis screening. Community Genetics (2000) 2-11